Drug-Resistance Mechanism and New Targeted Drugs and Treatments of Relapse and Refractory DLBCL
Author:
Publisher
Informa UK Limited
Subject
Oncology
Reference98 articles.
1. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray
2. Drug Resistance in Non-Hodgkin Lymphomas
3. The 2016 revision of the World Health Organization classification of lymphoid neoplasms
4. Mutational processes shape the landscape of TP53 mutations in human cancer
5. Multi-omics dataset to decipher the complexity of drug resistance in diffuse large B-cell lymphoma
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Non-neoplastic cells as prognostic biomarkers in diffuse large B-cell lymphoma: A system review and meta-analysis;Tumori Journal;2024-01-05
2. CAR-T cell therapy: Where are we now, and where are we heading?;Blood Science;2023-10
3. High G9a Expression in DLBCL and Its Inhibition by Niclosamide to Induce Autophagy as a Therapeutic Approach;Cancers;2023-08-17
4. Overexpression of MRP1/ABCC1, Survivin and BCRP/ABCC2 Predicts the Resistance of Diffuse Large B-Cell Lymphoma to R-CHOP Treatment;Cancers;2023-08-15
5. Role of RNA Splicing Mutations in Diffuse Large B Cell Lymphoma;International Journal of General Medicine;2023-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3